FDA Approves Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease (COPD)

Article Link: FDA Approves Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease (COPD)

November 09, 2018 — Today, the U.S. Food and Drug Administration (FDA) approved Yupelri (revefenacin) Inhalation Solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Revefenacin is a long-acting…

Source: FDA New Drug Approvals